Critical Pharmaceuticals and the University of Nottingham have announced a new partnership for development of a “nano-enabled” intranasal formulation of teriparatide for the treatment of osteoporosis. Funding for the £545,000 collaboration is coming from the Technology Strategy Board and the Engineering and Physical Sciences Research Council (EPSRC).
“We are excited about working with internationally-recognized clinicians and scientists at The University of Nottingham and Nottingham University Hospitals NHS Trust to rapidly develop this highly innovative formulation of teriparatide and look forward to the day we can offer it as an attractive alternative to daily injection for the many older people living with osteoporosis,” commented Critical CEO Gareth King.
Critical Pharmaceuticals’ CriticalSorb absorption promoter, a GRAS excipient, is used to enable transmucosal absorption of peptides and proteins. The company is also using CriticalSorb in its lead product, a nasal formulation of human growth hormone currently in Phase 1 clinical development.
Azelon Pharmaceuticals is also developing a teriparitide nasal spray and received funding in October 2011 to advance its program into Phase 2a.
Read the Critical Pharmaceuticals press release.
